Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy

J Infect Dis. 2006 May 15;193(10):1437-40. doi: 10.1086/503437. Epub 2006 Apr 4.

Abstract

We compared 156 human immunodeficiency virus (HIV)-infected patients who had tuberculosis with control populations of similar size. Of 111 patients with HIV infection and tuberculosis who received highly active antiretroviral therapy (HAART) and therapy for tuberculosis concurrently, 92 (83%) achieved or maintained virus loads of <50 copies/mL, and 99 (89%) achieved or maintained a >or=2 log10 reduction in virus load after 6 months. Virological response and changes in CD4 cell count were equivalent to those in 111 matched HIV-infected subjects without tuberculosis starting HAART. Tuberculosis recurrence rates were similar to those found in an HIV-uninfected population of 156 subjects (3% and 1%, respectively). Treatment for HIV and tuberculosis does not compromise outcomes for either disease.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiretroviral Therapy, Highly Active*
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • Drug Therapy, Combination
  • Female
  • HIV Infections*
  • Humans
  • London
  • Male
  • Medical Records
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*
  • Viral Load

Substances

  • Antitubercular Agents